RELA (also known as p65) is the key transcriptional activator subunit of the Nuclear Factor kappa-B (NF-κB) transcription factor complex. It plays a critical role in regulating inflammatory, immune, and cell survival responses in the central nervous system. In the context of neurodegenerative diseases, RELA-mediated NF-κB signaling is a major driver of neuroinflammation, a hallmark pathological feature of Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). [1]
The RELA gene (also known as NFKB3) encodes the p65 subunit, which is the principal transactivating component of the NF-κB heterodimer p65/p50. This protein is a member of the Rel homology domain (RHD) family and is essential for nearly all NF-κB-dependent gene transcription. In the brain, RELA is expressed in neurons, astrocytes, microglia, and oligodendrocytes, where it responds to various pathological stimuli including amyloid-beta plaques, alpha-synuclein aggregates, and mitochondrial dysfunction. [3]
The RELA protein contains several distinct structural domains: [4]
The three-dimensional structure reveals that RELA forms a butterfly-shaped dimer that clamps around DNA at κB enhancer sites, with each monomer contributing to transcription activation through protein-protein interactions with the basal transcription machinery. [5]
The canonical NF-κB pathway is activated by proinflammatory cytokines (TNF-α, IL-1β), pathogen-associated molecular patterns (LPS), and cellular stress. In the resting state, NF-κB dimers are sequestered in the cytoplasm by IκBα and other IκB proteins. Upon stimulation: [6]
RELA regulates hundreds of genes involved in:
In Alzheimer's disease, RELA activation occurs through multiple pathways:
The presence of activated RELA in the nuclei of neurons and glia near amyloid plaques suggests a direct role in AD pathogenesis. Studies have shown that Aβ-induced neurotoxicity is partially mediated through NF-κB-dependent gene expression.
In Parkinson's disease:
In ALS:
Several therapeutic strategies targeting RELA/NF-κB are being explored:
The pleiotropic nature of NF-κB signaling makes targeted therapy challenging, as complete inhibition could impair normal immune function and cell survival mechanisms. Selective modulation in specific cell types (e.g., microglia) remains an important research goal.
The study of Rela (P65) Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Mattson, M.P. & Meffert, M.K. (2006). Roles for NF-κB in nerve cell survival, plasticity, and disease. Cell Death & Differentiation, 13(5), 852-860. 2006. ↩︎
Kaltschmidt, B. & Kaltschmidt, C. (2009). NF-κB in the nervous system. Cold Spring Harbor Perspectives in Biology, 1(3), a001271. 2009. ↩︎
Chen, C.H. et al. (2012). NF-κB as a therapeutic target in neurodegenerative diseases. Expert Opinion on Therapeutic Targets, 16(12), 1177-1188. 2012. ↩︎
Sivandzade, F. et al. (2019). NF-κB inhibition in microglia: A potential therapeutic approach for Alzheimer's disease? Pharmacological Research, 147, 104361. 2019. ↩︎
Ghosh, S. & Hayden, M.S. (2008). New regulators of NF-κB in inflammation. Nature Reviews Immunology, 8(11), 837-848. 2008. ↩︎
O'Neill, L.A. & Bowie, A.G. (2007). The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nature Reviews Immunology, 7(5), 353-364. 2007. ↩︎